Ultrasound screening for cholangiocarcinoma could detect premalignant lesions and early-stage diseases with survival benefits: a population-based prospective study of 4,225 subjects in an endemic area

Table 5 Tumor marker analysis in the cases with and without cholangiocarcinoma

Predictor	Cholangiocarcinoma		Total	Sensitivity	Specificity	PPV	NPV
Predictor	Positive	Negative	Total	Sensitivity	Specificity	PPV	NPV
Positive CA19-9	6	59	65	18.75	98.63	9.23	99.39
Negative CA19-9	26	4245	4271
Total	32	4304	4336
Positive CEA	11	749	760	34.38	82.60	1.45	99.41
Negative CEA	21	3555	3576
Total	32	4304	4336
Positive ALP	15	641	656	50.00	83.54	2.29	99.54
Negative ALP	15	3254	3269
Total	30	3895	3925
Positive CA19-9 or CEA or ALP	22	1252	1274	68.75	70.91	1.73	99.67
Negative CA19-9 or CEA or ALP	10	3052	3062
Total	32	4304	4336

Abbreviations: CA19-9 carbohydrate antigen 19–9, CEA carcinoembryonic antigen, ALP alkaline phosphatase, NPV negative predictive value, PPV positive predictive value

ISSN: 1471-2407